Our Dividend Informer analysts suggest taking a look at the long-term prospects of this top-quality, high-yielding pharmaceutical company, even if its valuation is stretched.
The full analysis on this featured dividend stock is available only to paid Dividend Informer subscribers.
Continue reading this post for free, courtesy of Equity Research Service.